Kiora shareholders approve reverse stock split and increase authorized shares to 150M

An amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 150,000,000 was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,088,708 1,506,157 5,697 2,990,721

The compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with respect to the Annual Meeting was approved on a non-binding basis. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,291,900 1,224,207 84,455 2,990,721

The adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of any of the forgoing proposals at the time of the annual meeting was approved. However, the Company elected not to adjourn the meeting to solicit additional proxies for Proposal 4. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 17,206,128 377,890 16,544 2,990,721

An amendment to the Company’s Restated Certificate of Incorporation to adjust voting requirements for certain future amendments was not approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,329,852 1,254,063 16,647 2,990,721

The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. There were no broker non-votes on this proposal. The results of the vote were as follows: Votes For Votes Against Votes Abstained 18,896,438 1,622,946 71,899

The Company’s 2024 Equity Incentive Plan was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,153,997 1,360,851 85,714 2,990,721

The issuance, as contemplated by Nasdaq Listing Rule 5635, of up to 49,374,590 shares of Common Stock upon the exercise of Tranche A Warrants and Tranche B Warrants issued in a private placement completed in February 2024 was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,266,989 1,317,078 16,495 2,990,721

David Hollander, MD, MBA and Erin Parsons were elected as Class III Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such directors’ successors are duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes David Hollander, MD, MBA 16,555,192 1,045,370 2,990,721 Erin Parsons 16,478,582 1,121,980 2,990,721

An amendment to the Company’s Restated Certificate of Incorporation to effect a Reverse Stock Split of the shares of Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the Reverse Stock Split to be determined by the Company’s Board of Directors was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained 18,297,948 2,258,164 35,171